CV Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $3.00M | $0.00 | $0.00 |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $3.20M | $0.00 | $0.00 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $3.30M | $0.00 | $0.00 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $3.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | $3.60M | $0.00 | $0.00 |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $3.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | $3.90M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $3.90M | $0.00 | $0.00 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements CV Sciences filed with the SEC
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Fiscal Year-End 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 2 of 51
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PLEASE DO NOT CALL THE COURT OR CV SCIENCES REGARDING THIS NOTICE. Case 2:15-cv-00481-RFB-VCF Document 110-1 Filed 02/10/23 Page 6 of 6
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CV Sciences, Inc. Extinguishes Convertible Debt
Material agreement · Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Appoints Haskell & White LLP as Auditor
Auditor change · Regulation FD disclosure · EX-99.1 to Form 8-K
CV Sciences, Inc. Announces Closing of Convertible Note Financing
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
CV Sciences, Inc. Reports Third Quarter 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K